Literature DB >> 8871587

Origin and functional consequences of the complex I defect in Parkinson's disease.

R H Swerdlow1, J K Parks, S W Miller, J B Tuttle, P A Trimmer, J P Sheehan, J P Bennett, R E Davis, W D Parker.   

Abstract

The mitochondrial electron transport enzyme NADH:ubiquinone oxidoreductase (complex I), which is encoded by both mitochondrial DNA and nuclear DNA, is defective in multiple tissues in persons with Parkinson's disease (PD). The origin of this lesion and its role in the neurodegeneration of PD are unknown. To address these questions, we created an in vitro system in which the potential contributions of environmental toxins, complex I nuclear DNA mutations, and mitochondrial DNA mutations could be systematically analyzed. A clonal line of human neuroblastoma cells containing no mitochondrial DNA was repopulated with mitochondria derived from the platelets of PD or control subjects. After 5 to 6 weeks in culture, these cytoplasmic hybrid (cybrid) cell lines were assayed for electron transport chain activities, production of reactive oxygen species, and sensitivity to induction of apoptotic cell death by 1-methyl-4-phenyl pyridinium (MPP+). In PD cybrids we found a stable 20% decrement in complex I activity, increased oxygen radical production, and increased susceptibility to 1-methyl-4-phenyl pyridinium-induced programmed cell death. The complex I defect in PD appears to be genetic, arising from mitochondrial DNA, and may play an important role in the neurodegeneration of PD by fostering reactive oxygen species production and conferring increased neuronal susceptibility to mitochondrial toxins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8871587     DOI: 10.1002/ana.410400417

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  161 in total

Review 1.  Mitochondrial DNA analysis: polymorphisms and pathogenicity.

Authors:  P F Chinnery; N Howell; R M Andrews; D M Turnbull
Journal:  J Med Genet       Date:  1999-07       Impact factor: 6.318

Review 2.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

3.  Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.

Authors:  L Spahr; L Rubbia-Brandt; P R Burkhard; F Assal; A Hadengue
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

4.  Real-time monitoring of superoxide generation and cytotoxicity in neuroblastoma mitochondria induced by 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline.

Authors:  Sarah Jayne Boulton; Paul C Keane; Christopher M Morris; Calum J McNeil; Philip Manning
Journal:  Redox Rep       Date:  2012-05-30       Impact factor: 4.412

5.  alpha-synuclein promotes mitochondrial deficit and oxidative stress.

Authors:  L J Hsu; Y Sagara; A Arroyo; E Rockenstein; A Sisk; M Mallory; J Wong; T Takenouchi; M Hashimoto; E Masliah
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

6.  The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm.

Authors:  A R Esteves; M G-Fernandes; D Santos; C Januário; S M Cardoso
Journal:  Mol Neurobiol       Date:  2014-11-15       Impact factor: 5.590

Review 7.  Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas.

Authors:  Estela Area-Gomez; Cristina Guardia-Laguarta; Eric A Schon; Serge Przedborski
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

Review 8.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

9.  D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease.

Authors:  Kim Tieu; Celine Perier; Casper Caspersen; Peter Teismann; Du-Chu Wu; Shi-Du Yan; Ali Naini; Miquel Vila; Vernice Jackson-Lewis; Ravichandran Ramasamy; Serge Przedborski
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

10.  Unregulated mitochondrial GSK3beta activity results in NADH: ubiquinone oxidoreductase deficiency.

Authors:  Taj D King; Buffie Clodfelder-Miller; Keri A Barksdale; Gautam N Bijur
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.